Tag: biosimilars
Future Biosimilars: Upcoming Patent Expirations and Market Entry
Biosimilars are set to transform healthcare as major biologics like Keytruda and Eylea lose patent protection between 2025 and 2030. With billions in savings on the line, how will the U.S. market respond?
Read More
How Generic Medications Save Trillions in Healthcare Costs
Generic medications saved $467 billion in the U.S. healthcare system in 2024 alone, with $3.4 trillion saved over the past decade. Discover how generics cut drug costs by up to 90% and why more savings are still possible.
Read More
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic drugs in the U.S. enjoy 12 years of exclusivity before biosimilars can enter, delaying affordable alternatives. Learn how patent laws, complex development, and litigation block competition-and who pays the price.
Read More
Biologic Drugs: Why They Can't Be Copied Like Regular Medicines
Biologic drugs are made from living cells, not chemicals, making them too complex to copy exactly. That’s why biosimilars exist - they’re highly similar, but not identical. Learn why manufacturing them is like farming proteins, and why generics can’t compete.
Read More
What Are Biosimilars? A Simple Guide for Patients
Biosimilars are highly similar versions of complex biologic drugs that work just as well but cost less. Learn how they differ from generics, why they're safe, and what you need to know as a patient.
Read More